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(5), stroke(4)and heartdisease(2). Ourfindingsdo not supportthe belief
that the tX is a commoncauseof MHTamongstwomenof childbearing











hadan initialserumcreetinine(Cr) <300 wmolfl.Aftera medianfollow-up
of 53months(IQR15-103),51.6%(9W187)patientsdemonstrateda risein
serumCr.Patientswithan initialserumCr -=300wmol/1(Group1, n = 136)
wereoomparadwiththosewithCr>300 mmoWl(Group2, n=33); andthose
withan overallrfaein serumCr (GroupA, n = 38)werecomparedto those
withnorfseor a fallat follow-up(GroupB,n =91).
Results:mean@d.)
GrouP1 Group2 GroupA &ouP B
Aoe fV6WS) 49.5 [t4.o) 4s.s(10.3) 49.8(13.5) 4s.9 (13.0).g- ., .,
DurstfonofpriorHT(mths) 30.8 (58.3j 27.3(45.0) 33.6 (57.0) 25.6(54.5)
Inftfalurea (mmo!41) S.4 (3.7) 27.4 (16.S)” Io.e (9.7) 13.7 (12.5)
Initialcraatlne (Cr) (~mofll) 153 (58.6) 665 (450” 204 (155) 31s (399)+
SW atpraaan~tlon (mmHg) 230.0 (27.1) 328.8 (30.S) 230.1(29.2)229.3(25.8)
DBP at fxesentatlon(mmHg) 143.1 (19.6) 144.S (16.5) 143.8(20.3) 143,0 (17.4)
Follow-upurea (mmolrl) 11.7 (10.0) 29.7 (19.2)- 17.s (1s.5) 11.5 (8.7)+
Follow-upCreatinine (pmolll) 243 (295) 678 (333)* 409 (405) 223 (214)+
Follow-uPSBP (mmHg) 150.1 (30.5) 1s0.5 (3S.9)+ 170.0 (32.8) 156.0 (32.2)+
Fdlow-up DBP (mmHg) 95.6(17.3) 103.4(15.7)”” 100.2 (17.4) 93.0 (17.6)+
Follow-upduration(mtha) 70.1 (58.6) 33.4 (48.1)’ 61.9 (59.0) S4.4 (57.9)




ureaor Cr whencomparedto initial levels(pairedt-test,p = NS).In Group
1,therewasamarkeddeteriorationin renalfunctionat follow-up(meanrise
in serum Cr SO #moVt, Seruiw urea 3.3 mmolll; both p < 0.0001). Group2
patientshada lowermediansurvivalcomparedwithGroup1 (15monthsvs
59months,Lae-Deaustatistic=15.4,p=0.0001).Patientswithdeteriorating
renalfunction(GroupA) had higherinitial serumCr levelsand follow-up
BPswhencomparedto GroupB.Wesuggestthat renalfunctioncontinues













Thersautteof the EMIATtrialhaveshowna significantreduotionof arrhyth-
mia cardiacdeathsin post myocardialinfarctionpatients<75 yearswith




availablein 1181EMIATpts,a meannormal-to-normalRRintervals 850ms
(meansinusrhythmheartrate>--92 bpm)waspresentin74pts(20female,
meanage80.4& 9.9years).Of these,36 and38 werein the Amiodarone
andPlacebogroup,respectively.IntheAmiodaroneandPlacebogroupwith
increased 24-hour heart rate, there were 10 and 17deathsduringthe2 year
follow-up,respectively(27.8%vs447%). Cumulativesurvivorcufvesof pa-
tientswithincreasedmeanheartrateshowedclearseparation(Fig.:full line
= Amiodarone group,dashedline= Placebogroup)butbecauseof thesmall
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vlvorsofMl(meanage60+ 7yeara;Ml >6 monthsprevious)werescreened
forelevatedCptitres(lgG> 1/84)usingthemlcroimmunofluorescencet st.
60 eligiblepatientswererandomisedintoa double-blindprospectivestudy
and rsceiveda 3-daycourseof AZ(500mg/day)or placebo(P).A fufther
blindedooureeof Azor P wasgivenafter3 monthsto 45 of the original60
patients.Bloodsamplesweretakenat baseline,1,3 and6 monthsandthe
markers measured included monocyte tissue factor (MTF)and CDllb ex-
pression (flow cytometric, MESF unita), total Ieutxqte count (WCC), aerum
naopterin, fibrinogen, Factor Vlla and C-reactive protein levels. No signifi-
cant differences werenotedin anyof the markersin eitherAzor P groupet
baseline,1 or 3 months.At6 monthsthe sub-groupof patientsrandomised
to doubleAz therapy(at baselineandagainat 3 months,GroupAZAZn =
11)showeda significantfall in totalMTFandCDllb comparedto the sub-
groupof patientsreoeivingplacebo(GroupPP,n = 10)only (mean+ SEM,
AMTF:–20.3 + 11.5vs +14.6+ 11.1,p = 0.04;and ACDllb: -2.7 + 1.2
vs+1.6+ 0.9,p = 0.01).RepeatCpserologyat 6 monthsshowedthat5/11
(45%)AZAZpatients(comparedto 0/10PPpatients)hada significantdrop
in Cptitre(p= 0.04).These5 patientsalsohada fall in WCCandneopterin
(neop/creatinine)comparedtothe16patientswithunchangedtitres(AWCC:
-1.2 + 0.6 vs 0.1 + 0.2 x IOg/L,p = 0.05;and Aneop/creat:-3.6+ 2.3va
+0.8?C0.5nmol/umol,p = 0.03).Conclusion:Azithromycintherapyreduces
monocyteactivationandCpantibodyfitresin Post-Mlpatients.Theeffectof








Nimrandil (iV/CJis a potassiumATP-channelactivatorwith a nitrate like
activity Monotherepywith 10 to 20 mg bid of NIC has beenfound to be
efficaciousin stabieanginapaotorispatients.HoweverthetherapywithNIC
is associatedwithsomeincidenceof headacheas othervasodilators.Aim
of our double-blind,parallelgroupstudywasto comparethe incidenceof
adverseevents(AE),andparticularlyof headache,in twodoseregimensof
NICin patients(@) withetableangina.NICwasadministeredfor 6 weeka
in monotherapyat thedoseeof 5, 10,20 mgbid (A)or 10,20,20 mgbid (6I
(2weekaforeachdoseievei).Anadditionalaimof thestudywasto evaluate
efficacyof NICat eachdoseused.Aftera weekof wash-outand a weekof
placeborun-in,172patients(63A-69B)withreproducible xercisetolerance
test(ET7)wererandomised.Every2 weekssafetyandefficacy(ETT)were




ptS.W4thAE (%) 10(12) 19 (21.3)
AE 13 24
pta. withheadache (%) 8 (9.6)* 19(21.3)
drop-out(%) 5 (6) 6 (5.6)
EFFICACY reSUlt9
Ischemicthresh. llme (sec.) HR X BP prod.
A B A B
Basal 7.66 7.14 21812 22136
2 weeks 8,86? 8.Z5t 23789t 2322.7t
4 weeka 9.58? 9.lot 24030t 242s4t
6 weeks 9.9ot 9.46t 24569t 24564t
(*p <0.05 AvS B-CHI SQ.; tp < 0.05 vsbasal-ANOVA)
Cono/Uslorr: MC showeda goodsafetyprofile;the incidenceof AEand
particuladyof headachewassignificantlyloweringroupA.
No arrhythmiaswere obsewedand otherAEs occurredin a very low









motility by 11.2%at 42 days. Sinoeconoemsexist on eaferyof early
vasodilationafterMl,weusedtheGISSI-3databaee(19318pta)todescribe
(a)dosesof L usedin the200parficlpatlngCCU(75%of itelianCCU),and
(b)clinicaldeterminantsofLdosesinthefiret4daysandatdischarge.Target
daily L doseby protooolwee5 mgfor days1 and 2, then 10 mg upto 42
days;ptawithsystolicbloodpressure(SSP)s 120mmHgondays1 thru3
couldbe given2.5 rng.MeanL dose(mg)wason day 14.2 + 16(mean+
SD),day2 4.6+ 2.2,day36.3 + 3.5,day46.6 + 3.7,discharge(14days)
7.2 + 4.2.Variablealikelyto influenceL prescribeddosewereintroducedin
a multivariatelogisticmodelandyieidadthefollowingresults:(a)significant
determinantofuseof targetLdoeeondays1tfiru4 (?5 m@day)weshietory
of hypertension(OR1.44,95°76Cl, 1.28-1.80),whileptewithSBPat entry
of 10&120 mmHg(OR0.44,95%Cl 0.40-0.47),andpteaged>70 y (OR
0.85, 95% Ci 0.78-0.95) receivedlowerdoses;(b) determinantof useof
targetL doseat diacharge(210 mglday)was historyof hypertension(OR













Severalreoentstudieshave demonstratedthat, similarto acute Ml and
suddendeath, episodesof myocerdialischemiaalso havea diurnalpet-
tem withan increasedfrequencyanddurationin the morning(8 am-noon)
hours.Baeadon thesedata, it has beensuggestedthat administrationof
antiischemicdrugs beforebedtimemight be of greaterbenefit in raduc-
ing the risk of ischemiain the morning.Accordingly,in this double-biind,
placebo-ocmtrolled,multioanterstudy,we evaiuatedthe effioaoyof onoe-a-
day formulationof diltiazem,D (dilacorXR, Rhone-PouiencRorer)given
eitheras4S0mgdosebetween7% am or betweenS-10 pmin a random-
ized,crossovermanner.Forty-eight-hourambulatoryECGmonitoring(AEM)
wasperformedat baselineand at the end of eachstudyphaea.A total of
88 ptewith establishedCAD,stabieangina,andambulatoryiechemia(22
mink%h) oompletedall phasesof thestudy.At baselineprforto AMdosing
therewasanaverageof 2.1 + 3.2 ischemicepisodes(lEs)accountingfora
meandurationof 49 + 6Srein,andAMdosingwithD significantlyreduoed
theseto 0.9+ 1.4IEsand22+47 rein,respeorively(p < 0.002).Priorto the
PMdosingtheaverageIEswere1.5+ 1.4witha meandurationof 36 + 57
minandthe PMdosingwithD significantlyreducedtheseto 0.8 & 1.4IEs
and20A 42rein,respectively(p < 0.02).overall,D reduoadIEsby45%and
ischemicdurationby40%duringthemonitoringperiod.Compariarrnof AEM
datarevealedthatbothAMand PMdosingwith Dwereequallyeffectivein
reducingthe riskof ischemiain the morninghours,Theseresuksindicate










levelsof ET-1havabeensuggestedto beof importanceinthepathogenesis
of myocerdialischemia.Aimof the presentstudywasto evaluatethe effaot











Anerial 1.48 i 0.2 1.52A0.1
Comnary.sinus 1,53* 0.4 1.56+ 0.3
BseslinePacing
Coronarysinus 2.31 + 0.2 2,33 & 0.4
“hA-CSChange 44,6 ”/0 46,1%
Pacingsfter studydrug
Coronarysinus 2.07 & 0.3 2.32 + 0.4
O/.A-Cc Change 32.7% 45.9%*
Drugvs Basaiins Pacing –11.9”/0 –0.2%”
Values in ngrl;*p <0.01 E vs P; A = Arterial;Cs = Coronary sinue
In conclusion E reduces the ischamia-induoed oardiac release of ET-1.
Thia may contribute to the cardioprotactive effects of the horrnona.
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CardiactroponinI (cTni)has been shownto be a highiyapaoificmarker
of myocerdialiachemiaallowingdetectionof minormyooardialinjuryunde-
tectableby CK-MBmeasurement.We prospectivelystudied60 Pta(64 +




upperlimit of normal= 0.6 j@) and was aaaessed6, 12, 24, 48 end 72
h afteradmission.All Pfshada coronaryangiogramduringhospitalization
withquantitativeangiographicanalysisof theculpritlesionto aeaeesminimal
iumendiameter(MLD),% diameterstenosie(YoDS)and referenoediameter
(RD).Clinioalfaatures,T or STchanges,recurrenceof pain,MLD,RDand
% DSand needfor revascularisationwerecomparedin Ptswithor without
cTnlelevation.
